跳至主要内容
临床试验/NCT03451123
NCT03451123终止早期 1 期

FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors

University of Alabama at Birmingham1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2018年4月23日最近更新:
适应症
干预措施

试验速览

阶段
早期 1 期
状态
终止
入组人数
1
试验地点
1
主要终点
Percentage of patients who have residual tumor after surgery detected with FET-PET/MRI

研究概览

简要总结

The primary objectives of this study are:

  1. Determine the percentage of patients whose surgical plan would change with FET-PET/MRI compared to MRI alone.
  2. Determine the percentage of patients who have residual tumor after surgery detected with FET-PET/MRI.

A secondary objective of this study is:

  1. Perform preliminary correlations between the pre- and post-surgical metabolic tumor volumes measured with FET-PET/MRI to progression free survival.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
6 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Patient must have a known or suspected primary brain tumor with a non-enhancing component with planned standard of care surgical resection. Patients with newly diagnosed or recurrent brain tumors are eligible.
  • Tumors with non-enhancing regions will be defined as T2/FLAIR hyperintensity extending at least 0.5 cm beyond areas of enhancement as assessed by MRI.
  • Patient must be 18 years of age or younger at the time of study enrollment.
  • Patient must have measurable disease defined as tumor measurable in two perpendicular dimensions on MRI greater than 1 cm.
  • Patient must have a life expectancy greater than 8 weeks.
  • Patient must be able to undergo FET-PET/MRI without sedation.
  • Females with childbearing potential must have a negative urine β-hCG test on the day of procedure or a serum hCG test within 48 hours prior to the administration FET. Females who have not reached menarche will not require pregnancy testing.

排除标准

  • Patient must not be receiving an investigational or standard of care anti-cancer drug within 6 months prior to the FET-PET/MRI study.
  • Patient must not have received radiation therapy within the past 6 months.
  • Patient must not have a contraindication to contrast-enhanced MRI (e.g. renal insufficiency, incompatible implant).
  • Patient must not be pregnant or breast feeding.
  • Patient must not have been treated for another cancer within 5 years with the exception of cutaneous basal cell carcinoma or squamous cell carcinoma.
  • Patients must not have a history of brain metastases.

研究组 & 干预措施

FET-PET/MRI

Experimental

O-(2-[F-18]FET)-L-tyrosine (FET) for brain PET/MRI

干预措施: FET PET/MRI (Drug)

结局指标

主要结局

Percentage of patients who have residual tumor after surgery detected with FET-PET/MRI

时间窗: 2 years

The percentage of patients with residual tumor identified with FET-PET/MRI will be measured. This percentage will be compared to detection of residual tumor by MRI alone.

Percentage of patients whose surgical plan change with FET-PET/MRI compared to MRI alone.

时间窗: 2 years

Surgical planning will be performed prior to brain tumor resection based on MRI alone and then with FET-PET/MRI. The surgical margins will be compared and the percentage of patients whose surgical plans change with FET-PET/MRI will be calculated.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jonathan E McConathy

Principal Investigator

University of Alabama at Birmingham

研究点 (1)

Loading locations...

相似试验